Adverse events of drug-induced respiratory disorders in elderly people hospitalized in a secondary hospital: a pilot study

• Grant number: 21/05161-9
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: October 01, 2021
• End date: June 30, 2022
• Field of knowledge: Health Sciences - Pharmacy
• Principal Investigator: Patricia de Carvalho Mastroianni
• Grantee: Geovana Schiavo
• Host Institution: Faculdade de Ciências Farmacêuticas (FCFAR). Universidade Estadual Paulista (UNESP). Campus de Araraquara. Araraquara , SP, Brazil

Abstract

Adverse events of drug-induced respiratory disorders, although unusual in the general population, are common in the elderly, contributing to the worsening of the present morbidities and physiological changes of aging. Objectives: To estimate the prevalence of adverse events of drug-induced respiratory disorders in hospitalized elderly people using trigger tools, to identify possible risk factors, and to evaluate the performance of screening strategies. Methodology: A retrospective observational study will be conducted at the State Hospital of Américo Brasiliense, Brazil. The elderly admitted in the months of April, May, and June 2021 with signs and symptoms of respiratory disorders will be included and excluded with infection by COVID-19. Data collection will be conducted in three stages through consultations in the electronic medical record: i) screening of the elderly with signs and symptoms of respiratory disorders; ii) among potentially eligible patients, analysis of the use of drugs responsible for adverse events of respiratory disorders; iii) determination of the degree of causality between the use of the medication and the occurrence of the adverse event to the medication. The proposed trigger tools are drugs that can cause adverse events of drug-induced respiratory disorders and triggers adapted from the Global Trigger Tool; the performance of the trackers will be assessed by calculating the positive predictive value. Sociodemographic, clinical, pharmacotherapeutic, and lifestyle habits will be collected. A classification of the adverse event of respiratory disorders (with or without damage) and a review of pharmacotherapy will be carried out. Expected results: The study will help to identify the drugs with the most adverse respiratory disorders and which disorders are more frequent. If the trackers are more efficient in the identification, quantification, and monitoring of adverse events of respiratory disorders if a complementary strategy for the identification of respiratory disorders induced by drugs, thus avoiding an iatrogenic cascade and improving the safety of the elderly.(AU)